香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 之 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 就因 本 公 告全 部 或 任 何 部分 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致之 任 何 損 失承 擔任何責任。 合夥協議 於2025年8月6日（ 交易時段後 ），本公司有條件與懷格健康（ 作為普通合夥 人及基金管理人 ）及其他有限合夥人（ 作為有限合夥人 ）訂立合夥協議，內 容 有 關 設 立 懷 格 廣 泰 基 金 並 對 其 進 行 投 資 。 本 公 司 將 以 有 限 合 夥 人之一 的身份 投資懷格 廣泰基金 ，並將 認繳出資 不超過人 民幣110.0百萬元， 其 中，首期認繳出資為人民幣50.0百萬元。 懷 格 廣 泰 基 金 將 於 中 國 註 冊 為 一 家 有 限 合 夥 企 業 ， 主 要 目 標 為 通 過 對 醫 療 器 械 領 域 的 公 司 進 行 股 權 投 資 實 現 投 資 回 報 。 截 至 本 公 告 日 期 ， 懷 格 廣泰 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海瑛泰醫療器械股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01501 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 2. 股份分 ...

Shanghai INT Medical Instruments Co., Ltd.* 上海瑛泰醫療器械股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1501） 將 於2025年8月29日（星 期 五）舉 行 的 2025年第一次臨時股東大會及其任何續會的委託書 本人╱吾等 （附註1） 或 ， 地址為 為本人╱吾等的股東代理人出席將於2025年8月29日（星 期 五）下 午2時正於中國上海市嘉定區金園一 路925號2幢 舉 行 的 本 公 司 臨 時 股 東 大 會（「大 會」）及 其 任 何 續 會，並 代 表 本 人╱吾 等 於 會 上 作 出 行 動， 以考慮及酌情通過召開大會通告所載的決議案 （附註5） ，並代本人╱吾等及以本人╱吾等的名稱於大會（及 其 任 何 續 會）按 下 列 指 示 就 決 議 案 投 票。 | | （附註5） 特別決議案 | （附註6） 贊 成 | 反 對 | （附註6） | 棄 權 | （附註6） | | --- | --- | --- | --- | --- | --- | --- | | 1. | 審議及批准向本公司董事會授出一般授權，以配發、 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不就因本通告全部或任何部分內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 Shanghai INT Medical Instruments Co., Ltd.* 上海瑛泰醫療器械股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：1501） 2025年第一次臨時股東大會通告 茲通告 上 海 瑛 泰 醫 療 器 械 股 份 有 限 公 司（「本公司」）將 於2025年8月29日（星 期 五）下 午2時正於中國上海市嘉定區金園一路925號2幢舉行臨時股東 大 會（「臨時股東大會」），藉 以 審 議 及 酌 情 通 過 以 下 決 議 案（無 論 有 否 修 訂）： 特別決議案 * 僅供識別 – 1 – 1. (A) 審 議 及 批 准 授 予 董 事 會 一 般 授 權，以 於 有 關 期 間 內 配 發、發 行 及 處 理 額 外 內 資 股 及╱或H ...

此乃要件 請即處理 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 本通函僅供參考，並不構成收購、購買或認購 上海瑛泰醫療器械股份有限公司 任何證券的 邀請或要約。 閣下如 對本通函任何方面或將採取的行動 有任何疑問，應諮詢 閣下的股票經紀或其他註 冊證券交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓 名下所有 上海瑛泰醫療器械股份有限公司 的股份，應立即將本通函及 隨 附 的 委 託 書 送 交 買 主 或 承 讓 人，或 經 手 買 賣 或 轉 讓 的 銀 行、股 票 經 紀 或 其 他 代 理 商，以 便轉交買主或承讓人。 Shanghai INT Medical Instruments Co., Ltd.* 上海瑛泰醫療器械股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1501） (1) 建議發行股份的一般授權；及 (2) 2025年第一次臨時 股東大會通告 本封面頁所用詞彙與本通函所界定者具有 ...

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 之 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 就因 本 公 告全 部 或 任 何 部分 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致之 任 何 損 失承 擔任何責任。 Shanghai INT Medical Instruments Co., Ltd. * 上 海 瑛 泰 醫 療 器 械 股 份 有 限 公 司 （ 於中華人民共和國註冊成立的股份有限公司 ） （股份代號：1501） 補充公告 茲提 述上 海瑛泰 醫療器 械股 份有限 公司（「本 公司」）截 至2019年 、2020年、 2021年 、2022年 、 2023 年及 2024年 12月 31 日止 年度 的 年報（「年 報」）。 除另 有 界 定外 ， 本 公 告 所用 詞 彙 與 年報 所 界 定 者 具有 相 同 涵 義 。董 事 會 謹 向本 公司股東及潛在投資者提供進一步資料如下： 支付予監事的薪酬 2019年至2024年支付予監事的薪酬明細如下 ...

Company Overview - YingTai Medical (01501.HK) closed at HKD 24.750 on May 29, down 1.0% from the previous trading day, reaching a new low in nearly a year [1] - The company has a leading position in the domestic interventional cardiology device sector and is one of the few medical device manufacturers in China with complete industrial capabilities, including independent mold development, product research and development, equipment development, and sterilization [1][2] - YingTai Medical was established in 2006 and is listed on the main board of the Hong Kong Stock Exchange [1] Financial Performance - On the same day, the net capital outflow was HKD 6.93 million, with inflows of HKD 39,600 and outflows of HKD 108,910 [1] Product and Innovation - The company operates 16 subsidiaries focusing on various fields such as cardiology, peripheral, neurology, orthopedics, urology, ENT, exosome therapy, and ultrasound-focused non-invasive treatment [2] - As of June 30, 2024, the company holds 85 domestic registered products, 25 CE-certified products, and 20 FDA-certified products, along with 364 authorized patents and 199 pending patents [2] Recognition and Achievements - YingTai Medical has received multiple honors, including "National Specialized and New 'Little Giant'," "National Intellectual Property Advantage Enterprise," and "Shanghai Enterprise Technology Center" [2] - The company has been supported by over 70 government projects, including national and Shanghai innovation funds and major industrialization projects [2] Workforce and Future Vision - The company employs over 1,700 staff, with its main production base located in Jiading District, Shanghai [3] - YingTai Medical aims to become a globally recognized medical device group led by technological innovation, adhering to the development philosophy of "Innovation Serves Health, Quality Creates Excellence" [3]

Company Overview - Shanghai Yingtai Medical Devices Co., Ltd. is a leading player in the domestic interventional medical device sector, established in 2006 and listed on the Hong Kong Stock Exchange [1] - The company has a complete industrial capability including independent mold development, product research and development, equipment development, and sterilization [1] - Yingtai Medical has obtained ISO13485, CE, and FDA certifications, with products sold in over 70 countries and regions worldwide [1] Product and Innovation - The company operates 16 subsidiaries focusing on various fields such as cardiology, peripheral, neurology, orthopedics, urology, ENT, exosome therapy, and non-invasive ultrasound treatment [2] - As of June 30, 2024, the company holds 85 domestic registered products, 25 CE certified products, and 20 FDA certified products, along with 364 authorized patents and 199 pending patents [2] - Yingtai Medical has received numerous honors and government project supports, including being recognized as a "Little Giant" by the national government and included in the S&P Global "Sustainability Yearbook (China Edition) 2024" [2] Workforce and Future Vision - The company employs over 1,700 staff, with its main production base located in Jiading District, Shanghai [3] - Yingtai Medical aims to become a globally recognized medical device group led by technological innovation, adhering to the development philosophy of "Innovation Serves Health, Quality Creates Excellence" [3]

Group 1 - The company, Ying Tai Medical, has entered into a formal acquisition agreement to acquire a total of 81.83% equity in Hangzhou Weiqiang Medical Technology Co., Ltd. for approximately RMB 513 million, with the company acquiring 51.70% controlling interest for about RMB 324 million [1] - The acquisition is conditional and will only be finalized upon the completion or waiver of certain preconditions [1] - Following the acquisition, the target company will become a non-wholly owned subsidiary of Ying Tai Medical, and the company along with Chen Yue Weixin will inject no less than RMB 150 million into the target company [1] Group 2 - The target company specializes in the research, development, manufacturing, and sales of peripheral vascular interventional medical devices, which is a significant area of focus for the company's industry layout [2] - The acquisition is aimed at enhancing the company's product portfolio in the aortic and peripheral vascular interventional and implantable device sectors [2]

Financial Performance - The company's revenue for the year ended December 31, 2024, was approximately RMB 851.95 million, an increase of about 13.17% compared to RMB 752.84 million for the year ended December 31, 2023[9]. - Revenue from interventional medical devices was approximately RMB 773.33 million, representing a growth of about 15.23% from RMB 671.10 million in the previous year[9]. - The net profit for the year was approximately RMB 190.05 million, a 24.03% increase from RMB 153.23 million in the prior year[9]. - Basic and diluted earnings per share for the year were RMB 1.10, up from RMB 0.92 in the previous year[9]. - Gross profit for the year was RMB 537.66 million, resulting in a gross margin of 63.11%, up from 58.19% in the previous year[20]. - Net profit for the year was RMB 190.05 million, with a net profit margin of 22.31%, compared to 20.35% in 2023[20]. - The company achieved sales revenue of RMB 773.33 million from interventional medical devices, representing a 15.23% increase from RMB 671.10 million in the previous year[20]. - Other income decreased by approximately 18.13% to RMB 27.29 million compared to RMB 33.33 million for the year ended December 31, 2023[38]. Research and Development - The company has achieved 22 new product registrations during the reporting period, including 9 Class III medical device registrations and 13 Class II registrations[11]. - The company aims to expand its product pipeline and increase R&D investment to accelerate the development and approval of core and new products[13]. - The establishment of a research and development center will support the exploration of automation and scalable production potential for efficient manufacturing[13]. - R&D expenses for the reporting period were approximately RMB 189.93 million, an increase of 5.92% from RMB 179.31 million in the previous year, driven by ongoing product development and commercialization[42]. - The R&D team consists of professionals with PhDs and master's degrees, holding 406 registered patents and 215 pending patent applications[23]. Market Presence and Distribution - The distribution network covers 3,049 hospitals across 23 provinces, 4 municipalities, and 5 autonomous regions in China, along with 281 overseas customers in 86 countries and regions[10]. - The company holds 33 Class III medical device registrations and 61 Class II medical device registrations as of December 31, 2024[22]. - Revenue from interventional medical devices was approximately RMB 773.33 million, accounting for about 90.77% of total revenue, up from 89.14% in the previous year[35]. Strategic Initiatives - For 2025, the company plans to pursue strategic initiatives combining mergers and acquisitions with organic growth to enhance sustainable development[13]. - The company aims to drive synergistic development through both external acquisitions and organic growth strategies[33]. - The company has established joint ventures for asset management and sales of cosmetics and healthcare products, which are considered related party transactions[32]. Financial Position - Total assets as of December 31, 2024, amounted to RMB 2,259.88 million, an increase from RMB 2,029.63 million in 2023[20]. - Cash and bank balances as of December 31, 2024, were approximately RMB 521.95 million, up from RMB 423.67 million in the previous year[45]. - The total current assets as of December 31, 2024, were approximately RMB 892.13 million, compared to RMB 724.29 million as of December 31, 2023[45]. - The capital debt ratio increased to 13.64% as of December 31, 2024, from 5.65% in the previous year, with bank loans amounting to approximately RMB 227.26 million[46]. Shareholder Information - The largest customer accounted for 6.34% of total sales, while the top five customers collectively represented 20.57% of total sales[73]. - Major shareholders include Ningbo Huai Ge Tai Yi Equity Investment with 9,843,750 shares, representing 13.71% of the class shares and 5.59% of total shares[93]. - The company has a significant concentration of ownership, with multiple entities holding over 10% of shares[96]. - The company has adopted a dividend policy that allows for the declaration and payment of dividends based on various factors, including current and future operations and profitability[78]. Corporate Governance - The board of directors confirmed compliance with corporate governance codes, except for a minor deviation noted in the report[162]. - The company has maintained more than three independent non-executive directors since its listing in November 2019, complying with listing rules[169]. - The board consists of 7 male members and 2 female members, with 63.0% of the total 1,735 employees being female[167]. - The company has adopted a board diversity policy, considering factors such as gender, age, cultural background, and professional experience[167]. Risk Management - The board of directors is responsible for the group's risk management and internal control systems, which are reviewed annually[199]. - The company has implemented multiple policies and procedures for effective risk management, with the general manager holding ultimate responsibility[200]. - An internal audit department has been established to independently assess the adequacy and effectiveness of the company's risk management and internal control systems[200].